YN-001(YN-001) - 药物靶点：CD44 x HMG-CoA reductase_在研适应症：动脉粥样硬化，冠心病，心血管疾病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

靶点

CD44 x HMG-CoA reductase

作用机制

CD44抑制剂(CD44抗原抑制剂)、HMG-CoA reductase抑制剂(羟甲基戊二酰辅酶A合酶抑制剂)

治疗领域

心血管疾病

在研适应症

动脉粥样硬化冠心病心血管疾病

非在研适应症-

原研机构

北京茵诺医药科技有限公司

在研机构

北京茵诺医药科技有限公司

非在研机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)临床1/2期

特殊审评-

登录后查看时间轴

关联

3

项与 YN-001 相关的临床试验

NCT06048588 / Recruiting临床1/2期

A Phase I/IIa Trial to Evaluate the Safety, Tolerability, PK, and Preliminary Efficacy of Single and Multiple Ascending Doses of YN001 in Healthy Subjects and Multiple Ascending Doses of YN001 in Patient With Coronary Atherosclerosis

This study consists of two parts. The SAD and MAD of part I are a randomized, double-blind, placebo-controlled, single and multiple ascending dose study in healthy adult subjects. The MAD expansion cohort of part I is single arm and multipal ascending dose in heallthy subjects. Part II (phase Ib/IIa) is a multicenter, randomized, controlled, open label, multiple ascending dose study in patients with coronary atherosclerosis.

开始日期2023-10-08

申办/合作机构

北京茵诺医药科技有限公司

CTR20232962 / Recruiting临床1期

一项评价YN001在中国健康受试者中单次和多次给药及冠状动脉粥样硬化患者中多次给药的安全性、耐受性、药代动力学和初步疗效特征的剂量递增I期临床试验

Ia期主要目的：在中国健康受试者中，评估YN001单次和多次静脉给药剂量递增的安全性和耐受性及药代动力学特征。次要目的：在中国健康受试者中，评估YN001单次静脉给药剂量递增对QT/QTc间期的影响及多次静脉给药剂量递增的免疫原性。 Ib期主要目的：在冠状动脉粥样硬化患者中，评估YN001多次静脉给药剂量递增的安全性和耐受性；次要目的：在冠状动脉粥样硬化患者中，评估YN001多次静脉给药剂量递增的药代动力学特征、初步疗效、免疫原性和细胞因子变化。

开始日期2023-10-08

申办/合作机构

北京茵诺医药科技有限公司

NCT05635084 / Recruiting临床1期

A First-in-human, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered YN001 in Healthy Subjects

This will be a single center, randomized, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study in healthy adult subjects.

开始日期2022-12-16

申办/合作机构

北京茵诺医药科技有限公司

100 项与 YN-001 相关的临床结果

登录后查看更多信息

100 项与 YN-001 相关的转化医学

登录后查看更多信息

100 项与 YN-001 相关的专利（医药）

登录后查看更多信息

3

项与 YN-001 相关的文献（医药）

1997-03-01·Journal of Biochemistry4区 · 生物学

5-Aminolevulinate Synthase Expression and Hemoglobin Synthesis in a Human Myelogenous Leukemia Cell Line

4区 · 生物学

Article

作者: Hiroshi Munakata ; Kazumichi Furuyama ; Tadashi Nagai ; Hideo Harigae ; Macavnki Yamamoto ; Shifferu Sassa ; Norio Hayashi ; Kazuyasu Endo

We examined the effect of hemin, TGF-beta1 and cytosine arabinoside (Ara-C) on the levels of mRNAs for the erythroid-specific 5-aminolevulinate synthase (ALAS-E) and gamma-globin in various human myelogenous leukemia cell lines. Detailed analyses were also made using one of them, YN-1, which was isolated and established in culture from a patient with chronic myelogenous leukemia. Our results demonstrate that gamma-globin protein level and the percentage of benzidine-positive cells in the cell line increased markedly (10- to 30-fold) upon treatment with hemin, TGF-beta1, or Ara-C. In contrast, gamma-globin mRNA was already markedly expressed prior to treatment in 4 out of 9 cell lines examined, including YN-1, and the level increased only marginally after treatment with hemin. ALAS-E mRNA levels were increased in YN-1 cells after treatment with TGF-beta1 and Ara-C, while hemin treatment had little effect. These results indicate that heme supply is insufficient in YN-1 cells and suggest that hemin increases hemoglobin synthesis principally at the post-transcriptional level, whereas TGF-beta1 and Ara-C stimulate hemoglobin synthesis by activating efficient endogenous heme supply in the cells.

1987-12-01·Planta Medica3区 · 医学

Effects of an Active Substance Isolated from the Roots ofAngelica shkiokianaon Leukotriene and Monohydroxyeicosatetreaenoic Acid Biosyntheses in Human Polymorphonuclear Leukocytes

3区 · 医学

Article

作者: Arichi, Shigeru ; Okuda, Hiromichi ; Kozawa, Mitsugi ; Kimura, Yoshiyuki ; Baba, Kimiye

The EtOAc fraction of the roots of A. shkiokiana inhibited Ca ionophore-induced LTB₄ and LTC₄ formations in human polymorphonuclear leukocytes (PMN-L).The active substance, YN-1, isolated from this root of was characterized to be 3'(R),4'(R)-3'-epoxyangeloyloxy-4'-acetoxy-3',4'-dihydroseselin (I).I at concentrations of 4-400 μg/mL inhibited Ca ionophore-induced 12-hydroxyeicosatetraenoic acid, 5-hydroxyeicosatetraenoic acid, LTB₄, and LTC₄ formation in human PMN-L, dose-dependently, as shown by measurements with reversed phase HPLC and RIA.

Analytical Methods

A naphthalimide-tyrosine-based dicationic amphiphile for intracellular ‘turn-on’ simultaneous detection of ATP and CTP

Article

作者: Kumar, Sugandha ; Vanita, Vanita ; Sharma, Poonam ; Singh, Prabhpreet ; Marok, Satwinder Singh ; Walia, Amandeep

Novel 1,8-naphthalimide-based dicationic amphiphiles for ‘turn-on’ simultaneous concentration-based detection of triphosphates (ATP and CTP) in buffered solution and MCF-7 cells.

100 项与 YN-001 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
动脉粥样硬化	临床2期	中国	北京茵诺医药科技有限公司	2023-10-08
冠心病	临床1期	中国	北京茵诺医药科技有限公司	2023-10-08
心血管疾病	临床1期	澳大利亚	北京茵诺医药科技有限公司	2022-12-16